# Kamada Reports Record Revenue of $152.2 Million

*Third-quarter net profit jumped 51% to $8 million • The company raises its full-year 2026 guidance and expects double-digit growth in 2027 as well • A total dividend of about $8 million will be distributed to shareholders*

- Published: 2026-11-09T12:50:06.217Z (Monday, November 9, 2026)
- Updated: 2026-11-12T20:17:19.328Z
- By: Shai Nogai
- Section: TASE Stocks
- Canonical: https://tv10.news/news/capital-market/tase-stocks/126961/kamada-reports-record-revenue-of-152-2-million/
- Hebrew original (TV10): https://tv10.co.il/news/capital-market/tel-aviv-stocks/126961/
- Publisher: TV10 Global (TV10, Israel’s economic channel). Translated from Hebrew with AI and an automated accuracy check.

Israeli biopharmaceutical company Kamada, controlled by the FIMI fund, concluded an especially strong third quarter and reported record results for the first nine months of 2026.

![Laboratory, illustration](https://tv10.news/media/2026/11/a0/a0239e6fd13129d27003055b18459fb57bbca56fbcb77945b2339e82533e34d2.jpg)

Laboratory, illustration | Photo: Shutterstock

Following its operating and financial performance and growing demand for its products, Kamada raised its revenue and profitability guidance for the full year and expects its double-digit growth momentum to continue into 2027.

### Sharp jump in net profit and continued operating expansion

In the third quarter of 2026, the company’s revenue totaled $52.0 million, an increase of 11% compared with $47.0 million in the corresponding quarter last year. The growth was driven primarily by an increase in sales of KEDRAB in the U.S. market, alongside continued growth in sales of VARIZIG and HEPAGAM.

Gross profit in the quarter reached $23.3 million (45% of revenue), compared with $19.8 million (42% of revenue) in the third quarter of 2025, an improvement resulting from a more profitable sales and market mix.

![Revenue](https://tv10.news/media/2026/11/a7/a73e525572f445d40a100c23458a593f1d756cb7ee4afe1244256862d61d467e.jpg)

Revenue | Photo: Shutterstock

Kamada’s net profit jumped 51% to $8.0 million ($0.14 per diluted share), compared with $5.3 million in the corresponding quarter. Adjusted EBITDA for the quarter surged 30% to $15.2 million, representing about 29% of revenue.

In the first nine months of the year, Kamada posted record revenue of $152.2 million, an increase of 12% compared with the corresponding period, also supported by 35% growth in its distribution segment. Net profit for the nine-month period rose 29% to $21.4 million, while adjusted EBITDA for the period reached a record $40.9 million, an increase of 20%.

### 2026 guidance raised and optimism for 2027

In light of the results, the company’s management raised its annual revenue guidance for 2026 to a range of $205 million to $208 million, compared with the previous range of $200 million to $205 million.

Adjusted EBITDA guidance was updated to a range of $52 million to $54 million (compared with $50 million to $53 million previously), representing annual growth of about 26% at the midpoint.

![EBITDA](https://tv10.news/media/2026/11/b5/b5bbdf5be8121757f43ea758c133197c9e6d100f35467dc62e1b6d70d235c943.jpg)

EBITDA | Photo: Shutterstock

According to **Kamada CEO Amir London,** the company expects continued double-digit growth in revenue and profitability during 2027 as well, with detailed guidance to be presented in January 2027.

### Strong cash flow and distribution of about $8 million in dividends

Kamada’s operating activities generated robust cash flow of $37.6 million in the first nine months of the year, more than double the amount in the corresponding period. As of the end of September 2026, the company’s cash, cash equivalents and deposits totaled $75.3 million.

![Dividends](https://tv10.news/media/2026/11/5e/5e17faff8b0dded62d36a2ba5a6ab334041ed1f5cd67a5d6e4947e3270e28f0e.jpg)

Dividends | Photo: Shutterstock

Against the backdrop of its financial strength, the company’s board declared a cash dividend of $0.14 per share (about NIS 0.45), totaling about $8.0 million. Together with previous distributions, the total dividends paid by Kamada in 2026 amount to about $32.2 million ($0.56 per share).

### Growth engines and business expansion

Alongside its ongoing operations, Kamada continues to expand plasma collection activities at its three centers in Texas, intended to support a three-year supply agreement worth about $50 million with an international biopharmaceutical company.

![Medications. Photo: Shutterstock, New Africa](https://tv10.news/media/2026/11/b3/b304157d90737fa8adab512380bd9377df0f6f98ec8fbdc5141f39658b9128ee.jpg)

Medications | Photo: Shutterstock

At the same time, the company is expanding its biosimilar product portfolio in Israel with the launch of two additional new products and expects this field to generate revenue of about $10 million in 2028 and up to $20–25 million by 2030, while actively evaluating merger and acquisition opportunities to accelerate growth.
